» Articles » PMID: 39364434

The Role of Lactate Dehydrogenase in Exploring the Immune Evasion in HCC Patients Who Underwent TACE: Implications for Clinical Application

Overview
Date 2024 Oct 4
PMID 39364434
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To examine the relationship between lactate dehydrogenase (LDH) levels and soluble programmed cell death-ligand 1 (sPD-L1) levels in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).

Methods: A total of 83 hCC patients participated in this study. Patients were categorized into subgroups based on their alpha-fetoprotein (AFP) levels, presence or absence of extrahepatic metastasis, vascular invasion, Barcelona Clinic Liver Cancer (BCLC) stage, tumor response, tumor size, and number LDH and sPD-L1 levels were compared before and after TACE (3, 7, and 30 days post-TACE).

Results: LDH and sPD-L1 levels were significantly higher at 3 and 7 days post-TACE than at baseline. Positive correlations were observed between changes in LDH levels and sPD-L1 levels at 3 and 7 days post-TACE. LDH levels were higher in patients with elevated AFP compared to those in the normal AFP group at 3 and 7 days post-TACE, in the stable disease (SD) group compared to complete response (CR) and partial response (PR) groups at 7 days post-TACE, and in those with tumor > 5 cm compared with those with tumor ≤ 5 cm at 3 and 7 days after TACE (all < 0.05). sPD-L1 levels were higher in patients with vascular invasion than those without vascular invasion at 3 and 7 days post-TACE, in the SD group compared to CR and PR groups at 3 and 7 days post-TACE, and in those with tumor > 5 cm compared to those with tumor < 5 cm at 3 and 7 days after TACE (all < 0.05).

Conclusion: A positive correlation was found between LDH expression and sPD-L1 levels, suggesting LDH as a potential biomarker for assessing immune status in HCC patients following TACE.

References
1.
Xiaochen M, Xiangyang S, Fubo X, Wencheng J, Qingliang W, Yang X . The influence of transarterial chemoembolization on serum levels of soluble programed cell death ligand-1 in advanced hepatocellular carcinoma patients. Asia Pac J Clin Oncol. 2022; 18(5):e515-e523. DOI: 10.1111/ajco.13687. View

2.
Ai L, Xu A, Xu J . Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Adv Exp Med Biol. 2020; 1248:33-59. DOI: 10.1007/978-981-15-3266-5_3. View

3.
Zhuang G, Xie Y, Hong J, Lin S, Chen T, Fang W . Arterial chemoembolization for patients with hepatocellular carcinoma and elevated lactate dehydrogenase is associated with low survival: a cohort study. Infect Agent Cancer. 2022; 17(1):31. PMC: 9205044. DOI: 10.1186/s13027-022-00443-1. View

4.
Faloppi L, Bianconi M, Memeo R, Casadei Gardini A, Giampieri R, Bittoni A . Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. Biomed Res Int. 2016; 2016:7196280. PMC: 4903134. DOI: 10.1155/2016/7196280. View

5.
Liao J, Xiao J, Zhou Y, Liu Z, Wang C . Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma. Mol Med Rep. 2015; 12(4):6065-71. DOI: 10.3892/mmr.2015.4171. View